May 12, 2020 / 12:47 PM / 17 days ago

BRIEF-Seattle Genetics Announces Approval Of Tukysa (Tucatinib) In Switzerland For Treatment Of Patients With Metastatic Her2-Positive Breast Cancer

May 12 (Reuters) - Seattle Genetics Inc:

* SEATTLE GENETICS ANNOUNCES APPROVAL OF TUKYSA™ (TUCATINIB) IN SWITZERLAND FOR TREATMENT OF PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below